Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05349474 (ClinicalTrials.gov)	April 26, 2022	21/4/2022	Metformin Treatment in Progressive Multiple Sclerosis	A Double-blind, Placebo Controlled Trial of Metformin Treatment in Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Metformin 500 Mg Oral Tablet, up to 4 tablets a day;Drug: Placebo oral tablet identical to metformin, up to 4 tablets a day	University of California, Los Angeles	NULL	Recruiting	30 Years	65 Years	All	44	Early Phase 1	United States
2	NCT05131828 (ClinicalTrials.gov)	March 8, 2022	12/11/2021	CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy	CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy	Multiple Sclerosis	Drug: Metformin and clemastine in combination;Drug: Placebo	Cambridge University Hospitals NHS Foundation Trust	University of Cambridge	Recruiting	25 Years	50 Years	All	50	Phase 2	United Kingdom
3	NCT05298670 (ClinicalTrials.gov)	February 1, 2022	17/3/2022	Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients	Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients	Multiple Sclerosis	Drug: MetFORMIN 1000 Mg Oral Tablet;Drug: Interferon beta -1a	German University in Cairo	NULL	Recruiting	18 Years	50 Years	All	80	Phase 2	Egypt
4	NCT04121468 (ClinicalTrials.gov)	February 24, 2020	2/10/2019	A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis	A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: Metformin;Other: Placebo	The Hospital for Sick Children	Queen's University;Ontario Institute for Regenerative Medicine;Unity Health Toronto;Stem Cell Network;Multiple Sclerosis Society of Canada	Recruiting	10 Years	25 Years	All	30	Phase 1/Phase 2	Canada